TCBP's Business Model
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Sector & Industry | Healthcare / Biotechnology |
Website | https://www.tcbiopharm.com |
CEO (Chief Executive Officer) | Bryan Leland Kobel |
Number of Employees | |
IPO date | February 11, 2022 |
TCBP Latest News
|
|
|
|
|
Contact | |
---|---|
Country | GB |
Address | Maxim 1 |
City | Motherwell |
State | None |
Phone | 44 14 1433 7557 |
Zip Code | ML1 4WR |
Other Identifiers | |
CIK | 0001872812 |
ISIN | US87807D4007 |
CUSIP | 87807D103 |
Open | 1.51 |
Previous Close | 0.5 |
Volume | 5.9 Mil. |
Average Volume | 377.7 Thou. |
Day’s Range | 0.5 – 1.51 |
52 Week Range | 0.08-523.2 |
MA (50) | 3.18346 |
MA (200) | 48.27303 |
Market Cap | 256.5 Thou. |
Shares Out. | 513 Thou. |
Earnings Date | Feb 26, 2025 |
Beta | |
Last Dividend | |
EPS | |
PE | |